Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
LTT-462
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations. ### Output: LTT-462